BioStock: Chosa eyes publication of phase IIb-results

Danish biotech Chosa Oncology has had an eventful start of 2023. Following the RhoVac-transaction, the company is eagerly awaiting reply from an ASCO abstract application to publish phase IIb-results with its drug candidate LiPlaCis. CEO Peter Buhl comments on the Q4 report released earlier this week.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/03/chosa-eyes-publication-of-phase-iib-results/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se